Concordantly, KPC1 expression was downregulated in American Joint Committee on Cancer stage IV melanoma compared with early stages (stage I/II <i>P</i> = 0.013, stage III <i>P</i> = 0.004), and low KPC1 expression was significantly associated with poor overall survival in stage IV melanoma (<i>n</i> = 137; HR 1.810; <i>P</i> = 0.006).